Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;4(1):37-41.
doi: 10.1177/2040620712466863.

Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions

Affiliations

Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions

Patrizia Tosi et al. Ther Adv Hematol. 2013 Feb.

Abstract

Diagnosis and monitoring of multiple myeloma (MM) and related conditions are usually carried out by means of serum and urine protein electrophoresis and immunofixation. In the early 2000s, an assay aimed at evaluating serum free light chains (sFLCs) was made available and subsequently tested in different plasma cell disorders. Several reports have demonstrated the usefulness of the assay for the diagnosis and monitoring of oligosecretory MM, nonsecretory MM, Bence Jones MM, and amyloid light-chain amyloidosis. Furthermore, a prognostic role for an abnormal sFLC κ/λ ratio has been observed in the case of monoclonal gammopathy of unknown significance, smoldering MM, solitary plasmacytomas, and in newly diagnosed symptomatic MM secreting intact monoclonal immunoglobulins. In conclusion, according to present data, the sFLC assay can be considered reliable for the diagnosis, monitoring, and prognosis of different plasma cell disorders, and recently studies have been carried out to test a possible role of an sFLC evaluation in other B-cell lymphoproliferative malignancies.

Keywords: monoclonal immunoglobulins; myeloma; serum free light chains.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Similar articles

Cited by

References

    1. Bladè J., Kyle R. (1999) Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin N Am 13: 1259–1272 - PubMed
    1. Bradwell A., Carr-Smith H., Mead G., Harvey T., Drayson M. (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet 361: 489–491 - PubMed
    1. Bradwell A., Carr-Smith H., Mead G., Tang L., Showell P., Drayson M., et al. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673–680 - PubMed
    1. Charafeddine K., Jabbour M., Kadi R., Daher R. (2012) Extended use of serum free light chain as a biomarker in lymphoproliferative disorders. Am J Clin Pathol 137: 890–897 - PubMed
    1. Davids M., Murali M., Kuter D. (2010) Serum free light chain analysis. Am J Hematol 85: 787–790 - PubMed

LinkOut - more resources